Article Sidebar
Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Ameliorative effects of parecoxib in combination with ultrasound-guided paravertebral block (UGPB) on stress and inflammatory responses following thoracoscopic surgery
Abstract
Purpose: To investigate the ameliorative effects of parecoxib combined with ultrasound-guided paravertebral block (UGPB) on stress and inflammatory responses after thoracoscopic surgery.
Methods: Forty thoracoscopic surgery patients were randomized into placebo (control) and parecoxib groups. Parecoxib was administered pre-operation, 24 h and 48 h after operation. Arterial blood was collected, and endotoxin (ET), thromboxane A2 (TXA2), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels were measured. Opioid dosage, infusion volume, blood loss, operation time, visual analogue scale (VAS) score at 24 h and 48 h, and hospitalization period were recorded.
Results: No significant differences were observed in age, sex, height, body weight, opioid dosage, surgery time, blood loss, or infusion volume between groups. VAS scores in the parecoxib group were significantly lower than the control group after 24 and 48 h. The hospitalization period of the parecoxib group was significantly shorter than the control group. Plasma levels of ET, TXA2, IL-6 and TNF-α in the parecoxib group were lower than the control group after 24 h; however, there was no significant difference after 48 h.
Conclusion: Parecoxib, combined with UGPB, effectively relieves thoracoscopic pain, stress, and inflammatory responses of patients after thoracoscopic surgery. This treatment would improve the postoperative quality of life of lung cancer patients.
Keywords: Parecoxib, Paravertebral block, Stress response, Inflammatory response
